Scaling up fridge-free vaccines stable at +40°c

At Stablepharma, our mission is to revolutionise vaccine distribution and storage by leveraging our proprietaryStablevaX™ technology platform which results in the production of vaccines that are thermostable and do not require temperature controlled storage or distribution. Our technology can be applied to over 60 existing and currently, approved vaccines and our business model enable us to reformulate and thermostabilise existing, vaccines in partnership with vaccine manufacturers. By eliminating the need for cold-chain distribution and storage, we aim to enhance global access, reduce vaccine wastage, lower costs, and cut carbon emissions, all while enabling strategic stockpiling of vaccines. Our lead product is SPVX02 (a thermostable tetanus and diphtheria (Td) vaccine) and is currently positioned to enter the largest global human vaccine market by dose volume (tetanus and diphtheria-containing vaccines) aside from COVID-19 in recent years. SPVX02 addresses critical challenges in vaccine distribution and storage, especially in regions where cold-chain logistics create barriers to vaccine access. By stabilising vaccines at ambient temperatures, we extend the reach and impact of life-saving vaccines, to all populations worldwide. With the support of EIC funding, we intend to rapidly progress SPVX02 through a pivotal Phase 2b Clinical Trial, whilst collaborating with a range of EU-based manufacturing, clinical, and regulatory partners, before working with commercial distribution partners to apply for Market Authorisation in the EU and other regions. Ultimately, we plan to expand our portfolio to include additional thermostable vaccines and pharmaceuticals using our proprietary StablevaX™ technology platform enabling us to achieve our vision of saving lives and reducing wastage globally.